Medical necessity denials remain one of the most persistent challenges in healthcare revenue cycle management. While high-cost procedures and inpatient services often receive the most attention, a significant portion of denied claims stem from lower-cost, high-volume diagnostic services such as imaging and laboratory studies.
These services may not carry the price tag of a major surgical procedure, high-cost medication, or extended inpatient stay, but their sheer volume makes them a major contributor to preventable denials. For revenue cycle leaders, understanding how payers evaluate medical necessity for these services and where breakdowns occur is critical to improving both operational efficiency and financial performance.
How do payers define medical necessity for diagnostic services?
Medical necessity refers to whether a service is reasonable and necessary for the diagnosis or treatment of an illness or injury based on established clinical guidelines and payer policies. Third-party payers and insurers use medical necessity criteria to determine whether diagnostic services should be reimbursed.
In the context of imaging and laboratory testing, payers evaluate whether:
- The test is appropriate for the patient’s condition
- The clinical documentation supports the diagnostic purpose
- The ordering diagnosis aligns with payer policy criteria
- The service is not considered screening when billed as diagnostic
Unlike therapeutic services that treat a confirmed, defined condition, diagnostic tests are often ordered to evaluate potential disease, which introduces additional scrutiny from payers. This dynamic makes imaging and lab testing particularly susceptible to medical necessity denials.
Why are imaging and lab tests more susceptible to medical necessity denials?
Diagnostic services are inherently investigative rather than therapeutic and providers order them to gather information that may confirm or rule out a diagnosis. While this is essential to good clinical care, it can create challenges in the reimbursement process.
Adding complexity to denials management and authorization workflows in the lab and imaging space are third-party utilization management (UM) organizations.
These organizations are increasingly contracted by health plans to manage prior authorization and clinical policy for imaging and laboratory services. They apply proprietary clinical criteria and evidence-based guidelines (which may differ from both CMS standards and the ordering provider’s clinical judgment) to determine whether a requested service meets medical necessity requirements.
As a result, providers may encounter denials not because the service lacks clinical merit, but because the submitted documentation does not align with the criteria frameworks used by these third parties.
Denial management staff must understand not only the health plan’s coverage policies but also the distinct review criteria, portal requirements, and appeal pathways of each vendor. This makes it essential for revenue cycle and clinical documentation teams to stay current on payer-vendor relationships and the guidelines governing contracted services.
How do utilization management vendors affect denials management?
Payers require documentation that clearly demonstrates why the test is clinically appropriate for the patient at that time. When documentation or diagnosis codes do not align with payer policies, the claim may be denied.
Several factors contribute to these denials, including failure to meet payer-specific coverage criteria, insufficient diagnosis code specificity, and confusion between screening and diagnostic studies. Because imaging and laboratory testing are ordered millions of times each year, even minor documentation gaps can translate into large volumes of denied claims.
Certain diagnostic services appear consistently among the most frequently denied tests due to their high utilization and strict coverage policies. In the laboratory space, Vitamin D testing is one of the most commonly denied studies, as payers typically restrict coverage to specific conditions such as osteoporosis, chronic kidney disease, or malabsorption disorders. While Vitamin D testing is frequently ordered as part of an annual physical examination, it is not a recommended screening test and is therefore often denied when submitted without a qualifying diagnosis.
Lipid panels face similar challenges and may be denied when performed more frequently than payer guidelines allow, when billed outside of preventive care parameters, or when more advanced lipid testing is deemed experimental and investigational.
BNP (Brain Natriuretic Peptide) testing, a cardiac biomarker used in the evaluation of heart failure, is another common denial driver, particularly when the clinical indication is unclear or when unspecified ICD-10-CM codes and vague symptom-based diagnoses are submitted.
In imaging, CT scans and MRIs are frequently denied when documentation does not sufficiently support the clinical indication or when there is no evidence that conservative management requirements have been met prior to advanced imaging.
PET scans, particularly in oncology, are among the most heavily scrutinized studies, as payers and their utilization management partners apply strict, evidence-based criteria and prior authorization requirements to each request. As a result, appropriate ICD-10-CM code selection and precise, thorough clinical documentation are essential to reimbursement.
What clinical documentation gaps lead to the most common diagnostic denials?
Medical necessity denials affect more than just reimbursement. Healthcare organizations face increased administrative burden, delayed cash flow, and additional costs associated with appeals and rework. Physicians and clinical staff may spend valuable time addressing documentation gaps, participating in peer-to-peer reviews, or responding to payer inquiries.
For revenue cycle leaders already navigating workforce shortages and tight margins, these denials contribute to an increasingly complex operational landscape.
Consider a patient presenting with fever, vomiting, and right lower quadrant pain. The physician orders a CT scan of the abdomen and pelvis to evaluate possible appendicitis; however, the order is submitted with a general symptom code such as “abdominal pain, unspecified,” and the claim is denied.
In most cases, the difference between reimbursement and denial is driven by documentation specificity, alignment with payer policy requirements, and selection of the most appropriate ICD-10-CM code.
How can better clinical documentation and denial management strategies reduce diagnostic denials?
As diagnostic testing continues to grow, healthcare organizations must focus on improving alignment between clinical decision-making, documentation, and payer policy requirements. Technology solutions that integrate payer policy intelligence, clinical decision support, and revenue cycle analytics are increasingly helping organizations identify risks earlier in the ordering process.
By providing visibility into medical necessity requirements before services are performed, organizations can reduce preventable denials and support both clinicians and revenue cycle teams in delivering efficient, compliant care.
Ultimately, addressing medical necessity denials in imaging and laboratory testing is not only about protecting reimbursement; it’s about ensuring that clinical intent, documentation, coding, and payer policy are aligned from the start.
